Antiangiogenic Effects of BCG on Urinary Concentration of Angiogenic Factors

Terminated

• Conditions: Bladder Cancer

• Registration Number: NCT00216814
• Lead Sponsor: Lawson Health Research Institute

Brief Summary

To determine if there is an association between basic fibroblast growth factor,vascular endothelial growth factor, and interleukin levels and a patients response to BCG treatment ( as standard treatment)in the urine of patients with superficial TCC. To determine if the levels of these angiogenic factors can predict response to BCG, disease recurrence, progression risk factors.

Detailed Description

200 patients that are candidates for intravesical BCG therapy and 20 control patients with no history of malignancy will be enrolled. The study group wol;; be asked to provide a urine sample just prior to receiving their first BCG treatment(week # 1) and just prior to receiving their last (week # 6) BCG treatment. The control patients will provide one urine sample only. Samples will be analysed by enzyme-linked immunosorbant assay(ELISA). clinical data will be reviewed on tumor stage and grade prior to BCG, timme to recurrence, tumor stage and grade of recurrence, time to disease progression and death, cause of death and total follow-up time.

Study Timeline

• Study Start: 2003-10
• Study First Submitted: 2005-09-19
• Study First Submitted QC: 2005-09-19
• Study First Posted: 2005-09-22
• Study Completion: 2007-09
• Status Verified: 2008-01
• Last Update Submitted: 2008-04-18
• Last Update Posted: 2008-04-22

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 220

Inclusion Criteria

200 study group 1. Must be a candidate for BCG therapy. 20 control group 1. No history of malignancy.

Read More

Exclusion Criteria

• N/A

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

London Health Sciences Centre; 🇨🇦 London, Ontario, Canada